Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CHEK2 | O96017 | 4/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11949021 | 0.94 | KDR (0.51) | KDRSMN1; SMN2NPC1CHEK2SLC2A1 | |
| SCHEMBL11948994 | 0.89 | EGFR (0.52) | KDRHPGDSMN1; SMN2KDM4ENPC1 | |
| SCHEMBL11949036 | 0.88 | NR4A2 (0.47) | CHEK2 | |
| SCHEMBL11949004 | 0.88 | MMP2 (0.48) | HPGDKDM4EALDH1A1 | |
| SCHEMBL11949019 | 0.87 | SLC2A1 (0.52) | KDRHPGDSMN1; SMN2KDM4ENPC1 | |
| SCHEMBL11949032 | 0.86 | KDR (0.49) | KDRHPGDSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL11949020 | 0.85 | PRSS12 (0.61) | KDRCHEK2SLC2A1PRSS12 | |
| SCHEMBL11949049 | 0.83 | HDAC6 (0.45) | HPGDKDM4EALDH1A1 | |
| SCHEMBL11949014 | 0.83 | EGFR (0.53) | KDRHPGDSMN1; SMN2KDM4ENPC1 | |
| SCHEMBL11949025 | 0.83 | CHEK2 (0.48) | KDRSMN1; SMN2NPC1CHEK2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232410-B2 | Benzimidazoles and pharmaceutical compositions thereof | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232410-B2 | Benzimidazoles and pharmaceutical compositions thereof | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2012-07-31 | — | — | US | disclosed |
| US-20100256203-A1 | BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2010-10-07 | — | — | US | disclosed |
| US-20100256203-A1 | BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2010-10-07 | — | — | US | disclosed |
| WO-2008130669-A1 | BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256203-A1 | BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF | TBCD, TBC1D5, CFTR | KDR 4884/4885HPGD 2508/4885SMN1; SMN2 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.